MY194944A - Agents, Uses and Methods for the Treatment of Synucleinopathy - Google Patents

Agents, Uses and Methods for the Treatment of Synucleinopathy

Info

Publication number
MY194944A
MY194944A MYPI2017001926A MYPI2017001926A MY194944A MY 194944 A MY194944 A MY 194944A MY PI2017001926 A MYPI2017001926 A MY PI2017001926A MY PI2017001926 A MYPI2017001926 A MY PI2017001926A MY 194944 A MY194944 A MY 194944A
Authority
MY
Malaysia
Prior art keywords
disease
synucleinopathy
parkinson
agents
treatment
Prior art date
Application number
MYPI2017001926A
Other languages
English (en)
Inventor
Kallunki Pekka
Fog Karina
Buur Vesterager Louise
Bergstrom Ann-Louise
Sotty Florence
John Malik Ibrahim
Christina Pereira Montezinho Liliana
Satijn David
Van Den Brink Edward
Parren Paul
Rademaker Rik
Vink Tom
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MY194944A publication Critical patent/MY194944A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
MYPI2017001926A 2015-07-13 2016-07-12 Agents, Uses and Methods for the Treatment of Synucleinopathy MY194944A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
PCT/EP2016/066476 WO2017009312A1 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy

Publications (1)

Publication Number Publication Date
MY194944A true MY194944A (en) 2022-12-27

Family

ID=54013851

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017001926A MY194944A (en) 2015-07-13 2016-07-12 Agents, Uses and Methods for the Treatment of Synucleinopathy

Country Status (40)

Country Link
US (12) US10800836B2 (OSRAM)
EP (2) EP3322722B1 (OSRAM)
JP (4) JP7012004B2 (OSRAM)
KR (2) KR102793383B1 (OSRAM)
CN (2) CN115925921A (OSRAM)
AR (1) AR105336A1 (OSRAM)
AU (1) AU2016292896B2 (OSRAM)
CL (1) CL2018000075A1 (OSRAM)
CO (1) CO2017012941A2 (OSRAM)
CR (2) CR20180021A (OSRAM)
DK (1) DK3322722T3 (OSRAM)
DO (1) DOP2018000013A (OSRAM)
EA (1) EA036499B1 (OSRAM)
EC (1) ECSP18002645A (OSRAM)
ES (1) ES3028882T3 (OSRAM)
FI (1) FI3322722T3 (OSRAM)
GB (1) GB201512203D0 (OSRAM)
GE (1) GEP20207151B (OSRAM)
HR (1) HRP20250624T1 (OSRAM)
HU (1) HUE071541T2 (OSRAM)
IL (1) IL256501B (OSRAM)
JO (1) JO3692B1 (OSRAM)
LT (1) LT3322722T (OSRAM)
MA (1) MA42439B1 (OSRAM)
MX (2) MX2018000504A (OSRAM)
MY (1) MY194944A (OSRAM)
NI (1) NI201800006A (OSRAM)
PE (1) PE20181049A1 (OSRAM)
PH (1) PH12018500016A1 (OSRAM)
PL (1) PL3322722T3 (OSRAM)
PT (1) PT3322722T (OSRAM)
RS (1) RS66840B1 (OSRAM)
RU (1) RU2765303C2 (OSRAM)
SI (1) SI3322722T1 (OSRAM)
SV (1) SV2018005612A (OSRAM)
TN (1) TN2018000005A1 (OSRAM)
TW (1) TWI729992B (OSRAM)
UA (1) UA125501C2 (OSRAM)
WO (1) WO2017009312A1 (OSRAM)
ZA (1) ZA201708607B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
KR102623819B1 (ko) 2017-03-27 2024-01-10 체이스 테라퓨틱스 코포레이션 시누클레인병변을 치료하기 위한 조성물 및 방법
WO2018204352A1 (en) 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2019040617A1 (en) 2017-08-23 2019-02-28 The Trustees Of The University Of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
JP7212391B2 (ja) 2017-12-14 2023-01-25 エービーエル バイオ インコーポレイテッド ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
MX2020007904A (es) 2018-01-26 2020-09-07 Quantum Si Inc Llamado de pulso y base habilitado por maquina de aprendizaje para dispositivos de secuenciacion.
WO2019157527A2 (en) * 2018-02-12 2019-08-15 The Scripps Research Institute Methods related to parkinson's disease and synucleinopathies
CN112839710B (zh) * 2018-08-09 2024-09-17 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
WO2020212593A1 (en) * 2019-04-18 2020-10-22 Ac Immune Sa Novel molecules for therapy and diagnosis
WO2020223310A2 (en) * 2019-04-29 2020-11-05 Thomas Jefferson University Methods for treating neurodegenerative disorders
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
KR102466943B1 (ko) * 2020-04-02 2022-11-14 한국과학기술연구원 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
JP2024534901A (ja) * 2021-09-01 2024-09-26 ヴァクシニティ， インコーポレイテッド シヌクレイノパチーの予防及び治療のための方法
CN117915952A (zh) 2021-09-16 2024-04-19 H.隆德贝克有限公司 用于治疗突触核蛋白病的组合物和方法
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
WO2024177999A2 (en) * 2023-02-21 2024-08-29 The Regents Of The University Of Michigan Human aggregated alpha-synuclein binding molecules
CN116077524A (zh) * 2023-02-27 2023-05-09 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途
WO2025076635A1 (en) * 2023-10-12 2025-04-17 Universite Laval Anti-alpha-synuclein antibodies and uses thereof
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02504672A (ja) 1986-12-15 1990-12-27 ブリティッシュ　テクノロジー　グループ　ユーエスエイ，インコーポレイテッド 単量体性フタロシアニン試薬
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0486622B1 (en) 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
CN1440420A (zh) 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α－共核蛋白疾病的方法
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
EA013752B1 (ru) * 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
PL3067066T3 (pl) 2007-02-23 2019-09-30 Prothena Biosciences Limited Zapobieganie i leczenie choroby synukleinopatycznej i amyloidogennej
PL2154969T3 (pl) * 2007-05-16 2016-04-29 Brigham & Womens Hospital Inc Leczenie synukleinopatii
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
EP3470079A1 (en) 2008-04-29 2019-04-17 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
EA030826B1 (ru) * 2008-12-19 2018-10-31 Панима Фармасьютикалз Аг ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА
WO2010118282A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
ES2661925T3 (es) 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
PT2627672T (pt) 2010-10-11 2018-11-16 Univ Zuerich Anticorpos anti-tau humanos
ES2699801T3 (es) 2011-06-23 2019-02-12 Biogen Int Neuroscience Gmbh Moléculas de unión anti-alfa sinucleína
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
PT3378535T (pt) * 2011-10-28 2023-02-06 Prothena Biosciences Ltd Anticorpos humanizados que reconhecem a alfa-sinucleína
KR20200013072A (ko) 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2924268C (en) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
EP3207057A2 (en) 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
CA2985366A1 (en) 2015-05-07 2016-11-10 Axovant Sciences Gmbh Methods of treating a neurodegenerative disease
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10160800B2 (en) 2016-06-02 2018-12-25 Medimmune Limited Antibodies to α-synuclein and uses thereof
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Also Published As

Publication number Publication date
ECSP18002645A (es) 2018-03-31
JP2021191763A (ja) 2021-12-16
US10364285B2 (en) 2019-07-30
FI3322722T3 (fi) 2025-06-05
BR112017027506A2 (pt) 2018-09-11
US10358483B2 (en) 2019-07-23
US20210054057A1 (en) 2021-02-25
RU2765303C2 (ru) 2022-01-28
JO3692B1 (ar) 2020-08-27
AR105336A1 (es) 2017-09-27
NZ738315A (en) 2024-12-20
IL256501B (en) 2021-10-31
US10358484B2 (en) 2019-07-23
RS66840B1 (sr) 2025-06-30
DK3322722T3 (da) 2025-05-26
JP7608404B2 (ja) 2025-01-06
US10800836B2 (en) 2020-10-13
US20230312693A1 (en) 2023-10-05
PE20181049A1 (es) 2018-07-03
US10640554B2 (en) 2020-05-05
MA42439B1 (fr) 2025-05-30
PT3322722T (pt) 2025-05-21
US20180127492A1 (en) 2018-05-10
US10647764B2 (en) 2020-05-12
JP2018529634A (ja) 2018-10-11
WO2017009312A1 (en) 2017-01-19
US10358482B2 (en) 2019-07-23
RU2017145653A (ru) 2019-08-13
RU2017145653A3 (OSRAM) 2019-11-21
SV2018005612A (es) 2018-07-20
KR102793383B1 (ko) 2025-04-08
EA036499B1 (ru) 2020-11-17
EP4582144A3 (en) 2025-07-16
US11524995B2 (en) 2022-12-13
UA125501C2 (uk) 2022-04-13
GEP20207151B (en) 2020-09-25
HRP20250624T1 (hr) 2025-07-18
US11542323B2 (en) 2023-01-03
US20190367594A1 (en) 2019-12-05
CN107709361A (zh) 2018-02-16
AU2016292896B2 (en) 2022-02-24
ES3028882T3 (en) 2025-06-20
GB201512203D0 (en) 2015-08-19
JP2022174131A (ja) 2022-11-22
DOP2018000013A (es) 2018-04-15
EP3322722A1 (en) 2018-05-23
KR20180029205A (ko) 2018-03-20
US20210147522A1 (en) 2021-05-20
PH12018500016A1 (en) 2018-07-09
NI201800006A (es) 2018-10-18
MX2018000504A (es) 2018-04-30
US20180127491A1 (en) 2018-05-10
SI3322722T1 (sl) 2025-06-30
CL2018000075A1 (es) 2018-05-11
US20180179270A1 (en) 2018-06-28
MA42439A (fr) 2018-05-23
JP2025041734A (ja) 2025-03-26
EP4582144A2 (en) 2025-07-09
US20180179271A1 (en) 2018-06-28
JP7138322B2 (ja) 2022-09-16
US20190382473A1 (en) 2019-12-19
CN115925921A (zh) 2023-04-07
US11421024B2 (en) 2022-08-23
CR20230300A (es) 2023-08-25
LT3322722T (lt) 2025-06-10
PL3322722T3 (pl) 2025-06-30
EP3322722B1 (en) 2025-03-05
HK1254358A1 (en) 2019-07-19
JP7012004B2 (ja) 2022-02-10
EA201792616A1 (ru) 2018-06-29
AU2016292896A1 (en) 2018-01-18
US10647763B2 (en) 2020-05-12
US20210061892A1 (en) 2021-03-04
KR20250051158A (ko) 2025-04-16
US20170015739A1 (en) 2017-01-19
ZA201708607B (en) 2019-05-29
TN2018000005A1 (en) 2019-07-08
CO2017012941A2 (es) 2018-03-09
HUE071541T2 (hu) 2025-09-28
TW201716440A (zh) 2017-05-16
MX2023009483A (es) 2023-08-22
CR20180021A (es) 2018-03-13
CA2989735A1 (en) 2017-01-19
TWI729992B (zh) 2021-06-11
US20190367595A1 (en) 2019-12-05
IL256501A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12019502002A1 (en) Combination theraphy
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018500578A1 (en) Methods of treating inflammatory diseases
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MY202315A (en) Anti-trkb antibodies
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2016008968A (es) Compuestos organicos.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders